Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06079671 · ClinicalTrials.gov registry record · Phase 3

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

A Phase 3 study of Locally Advanced Cervical Cancer, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 3
Development phase
800
Enrollment target
20
Study locations

NCT06079671: Recruiting Phase 3 study of Locally Advanced Cervical Cancer, sponsored by AstraZeneca.

NCT06079671 is a Phase 3 study of Locally Advanced Cervical Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 800 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06079671, a Phase 3 study of Locally Advanced Cervical Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 3
Development phase
800 participants
Enrollment target
20
Study locations

Study Summary

This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.

Primary Outcome

PFS is defined as the time from date of randomization until RECIST 1.1- defined radiological progression or histopathologically confirmed progression as assessed by the Investigator or death due to any cause, whichever occurs earlier.

Conditions Studied

Locally Advanced Cervical Cancer

Interventions

  • OTHER Placebo
  • BIOLOGICAL Volrustomig

Study Locations (20)

Georgia

  • Research Site - Atlanta
  • Research Site - Augusta
  • Research Site - Savannah

Louisiana

  • Research Site - New Orleans
  • Research Site - New Orleans
  • Research Site - Shreveport

Arizona

  • Research Site - Phoenix
  • Research Site - Tucson

California

  • Research Site - La Jolla
  • Research Site - West Hollywood

New York

  • Research Site - New York
  • Research Site - Syracuse

Ohio

  • Research Site - Cleveland
  • Research Site - Columbus

Alabama

  • Research Site - Birmingham

Arkansas

  • Research Site - Little Rock

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2023-09-22
Est. Completion 2030-09-30
Phase Phase 3
AstraZeneca

1,285 total trials

What NCT06079671 shows while recruiting

NCT06079671 is an interventional study that assigns participants to a tested intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.

The record links to 1 condition, with Locally Advanced Cervical Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06079671 names 20 study sites across 12 states, led by Georgia, Louisiana, Arizona.

Frequently Asked Questions

What is clinical trial NCT06079671 about?

NCT06079671 is a clinical study titled "Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)". This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.

What is the current status of trial NCT06079671?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 2023-09-22. Estimated completion is 2030-09-30.

What conditions does trial NCT06079671 study?

This clinical trial studies the following conditions: Locally Advanced Cervical Cancer.

What interventions are being tested in trial NCT06079671?

The interventions under investigation include: Placebo (OTHER), Volrustomig (BIOLOGICAL).

Who is sponsoring clinical trial NCT06079671?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06079671 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Locally Advanced Cervical Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06079671's enrollment target sits among peer trials

800 414th of 2000 higher than 1,574 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00695214 · 800 participants · Phase 2

    Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea

  • NCT03048201 · 800 participants · NA

    Physica System Total Knee Replacement Registry Study

  • NCT03792659 · 800 participants

    The EXPLORE MG Registry for Myasthenia Gravis

  • NCT03819296 · 800 participants · Phase 1

    Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06079671

Source: ClinicalTrials.gov NCT06079671, the US trial registry maintained by the National Library of Medicine. NCT06079671 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.